KR20180042300A - Mrka 폴리펩티드, 항체 및 이의 용도 - Google Patents

Mrka 폴리펩티드, 항체 및 이의 용도 Download PDF

Info

Publication number
KR20180042300A
KR20180042300A KR1020187007376A KR20187007376A KR20180042300A KR 20180042300 A KR20180042300 A KR 20180042300A KR 1020187007376 A KR1020187007376 A KR 1020187007376A KR 20187007376 A KR20187007376 A KR 20187007376A KR 20180042300 A KR20180042300 A KR 20180042300A
Authority
KR
South Korea
Prior art keywords
mrka
seq
antibody
binding protein
antigen binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020187007376A
Other languages
English (en)
Korean (ko)
Inventor
췬 왕
사라바난 라잔
츄-? 창
츄-šœ 창
톰프슨 제니 하이드브링크
훙-유 린
찰스 켄달 스토버
메간 펜니니
윌리엄 달라쿠아
파르타 에스 초우두리
샤오동 샤오
Original Assignee
메디뮨 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메디뮨 엘엘씨 filed Critical 메디뮨 엘엘씨
Publication of KR20180042300A publication Critical patent/KR20180042300A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0266—Klebsiella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
KR1020187007376A 2015-08-24 2016-08-23 Mrka 폴리펩티드, 항체 및 이의 용도 Withdrawn KR20180042300A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562208975P 2015-08-24 2015-08-24
US62/208,975 2015-08-24
US201562238828P 2015-10-08 2015-10-08
US62/238,828 2015-10-08
PCT/US2016/048221 WO2017035154A1 (en) 2015-08-24 2016-08-23 Mrka polypeptides, antibodies, and uses thereof

Publications (1)

Publication Number Publication Date
KR20180042300A true KR20180042300A (ko) 2018-04-25

Family

ID=58100831

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187007376A Withdrawn KR20180042300A (ko) 2015-08-24 2016-08-23 Mrka 폴리펩티드, 항체 및 이의 용도

Country Status (16)

Country Link
US (2) US20170073397A1 (enExample)
EP (1) EP3341004A4 (enExample)
JP (1) JP2018527924A (enExample)
KR (1) KR20180042300A (enExample)
CN (1) CN107921086A (enExample)
AU (1) AU2016313653A1 (enExample)
BR (1) BR112018003252A2 (enExample)
CA (1) CA2995387A1 (enExample)
CL (1) CL2018000357A1 (enExample)
CO (1) CO2018001985A2 (enExample)
HK (1) HK1252350A1 (enExample)
IL (1) IL257434A (enExample)
MX (1) MX2018001964A (enExample)
RU (1) RU2018107056A (enExample)
TW (1) TW201718626A (enExample)
WO (1) WO2017035154A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201900027XA (en) * 2016-08-05 2019-02-27 Medimmune Llc Anti-o2 antibodies and uses thereof
WO2018075375A1 (en) 2016-10-19 2018-04-26 Medimmune, Llc Anti-o1 antibodies and uses thereof
JP2020525540A (ja) 2017-06-23 2020-08-27 ノソコミアル ヴァクスィーン コーポレイション 免疫原性組成物
CN115838430A (zh) * 2022-07-08 2023-03-24 中国人民解放军陆军军医大学 一种肺炎克雷伯菌的重组蛋白MrkD及其作为疫苗抗原的应用
CN116813725B (zh) * 2023-07-06 2025-11-04 深圳康泰生物制品股份有限公司 肺炎克雷伯菌的FimA的抗原表位肽及其应用
CN119798389A (zh) * 2024-12-12 2025-04-11 中国人民解放军军事科学院军事医学研究院 一种含脂肪酸化修饰的重组MrkA蛋白的免疫组合物及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020062010A1 (en) * 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
WO2001010386A2 (en) * 1999-08-11 2001-02-15 Washington University Anti-bacterial compounds directed against pilus biogenesis, adhesion and activity; co-crystals of pilus subunits and methods of use thereof
US7041465B1 (en) * 1999-08-11 2006-05-09 Washington University Anti-bacterial compounds directed against pilus biogenesis, adhesion and activity; co-crystals of pilus subunits and methods of use thereof
WO2005034733A2 (en) * 2003-10-08 2005-04-21 North Shore-Long Island Jewish Research Institute Methods and compositions for diagnosis and treatment of b cell chronic lymphocytic leukemia
EA018030B1 (ru) * 2006-06-06 2013-05-30 Круселл Холланд Б.В. Связывающие молекулы человека, имеющие убивающую активность против стафилококков, и их применения
GB0615662D0 (en) * 2006-08-07 2006-09-13 Affitech As Antibody
EP2152731A2 (en) * 2007-05-02 2010-02-17 Intercell AG Klebsiella antigens
GB0915403D0 (en) * 2009-09-04 2009-10-07 London School Hygiene & Tropical Medicine Protein glycosylation
WO2011100700A2 (en) * 2010-02-12 2011-08-18 University Of Rochester Antigenic mimics of discontinuous epitopes of pathogen recognized by broadly neutralizing antibodies
WO2012058334A1 (en) * 2010-10-26 2012-05-03 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University Morphology & protein specific reagents as diagnostics for neurodegenerative diseases
SMT202000542T1 (it) * 2011-11-07 2020-11-10 Medimmune Ltd Terapie di combinazione utilizzando molecole di legame anti-psl e pcrv di pseudomonas

Also Published As

Publication number Publication date
HK1252350A1 (zh) 2019-05-24
CL2018000357A1 (es) 2018-07-20
JP2018527924A (ja) 2018-09-27
TW201718626A (zh) 2017-06-01
US20170073397A1 (en) 2017-03-16
AU2016313653A1 (en) 2018-04-12
CO2018001985A2 (es) 2018-11-22
IL257434A (en) 2018-04-30
RU2018107056A (ru) 2019-09-26
CN107921086A (zh) 2018-04-17
MX2018001964A (es) 2018-06-19
US20190062411A1 (en) 2019-02-28
EP3341004A1 (en) 2018-07-04
EP3341004A4 (en) 2019-05-15
WO2017035154A1 (en) 2017-03-02
BR112018003252A2 (pt) 2018-09-25
CA2995387A1 (en) 2017-03-02

Similar Documents

Publication Publication Date Title
US20240383969A1 (en) Anti-o1 antibodies and uses thereof
US12312397B2 (en) Anti-O2 antibodies and uses thereof
US20190062411A1 (en) Mrka polypeptides, antibodies, and uses thereof
CN119176871A (zh) 抗金黄色葡萄球菌凝集因子a(clfa)的抗体
US10882899B2 (en) Anti Francisella tularensis (FT) antibodies
HK1248576A1 (en) Mrka polypeptides, antibodies, and uses thereof
HK40009426A (en) Anti-o1 antibodies and uses thereof
HK40007861A (en) Anti-o2 antibodies and uses thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20180314

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination